Latest News

Sage antidepressant achieves goals of study, but questions linger

Sage Therapeutics said Tuesday that an experimental pill designed to alleviate depression with a two-week course of therapy was successful in a large clinical trial involving patients with major depressive disorder.

The Sage drug, called zuranolone, demonstrated a statistically significant, anti-depressive benefit compared to a placebo. The positive results are a comeback win for Sage and its efforts to develop zuranolone for several different depressive disorders. The drug failed a similar study in December 2019.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Adam Feuerstein

Create a display name to comment

This name will appear with your comment

Read More

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker